Metrics as of 10/16/2026, 08:46 AM (Berlin time), refresh in progress.
Edesa Biotech Stock
Edesa Biotech, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- CEO
- Pardeep Nijhawan
- Employees
- 17
- Market cap
- $26 M
- IPO
- 21/06/2010
Edesa Biotech, Inc. is a biopharmaceutical firm focused on discovering, developing, and commercializing clinical-stage treatments for inflammatory and immune system disorders where current medical options are inadequate. The company's key pipeline assets include EB05, a monoclonal antibody undergoing a Phase 3…
Edesa Biotech stock: price history
1D
+0.8%
1W
-27.0%
1M
-35.2%
6M
-48.1%
YTD
+88.0%
1Y
+5.1%
2Y
-35.8%
5Y
-95.1%
10Y
-99.6%
Next earnings date
Next earnings date
11/12/2026 (in 55 days)
Volatility around earnings
~20% stronger price swings than usual
Ask the agents about Edesa Biotech
Analyst assessment of Edesa Biotech
0
STRONG BUY
2
BUY
0
HOLD
0
SELL
0
STRONG SELL
2
TOTAL · Buy
As of: 03/11/2025
Edesa Biotech stock metrics
P/E
-1.58
P/B
2.73
EV/EBITDA
-1.08
RETURN ON EQUITY
-61.4%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
79.7%
FLOAT SHARES
7,680,527
AVG. DAILY VOLUME (30D)
42,498
Insider transactions (SEC)
Nijhawan Pardeep
Nijhawan Pardeep
Nijhawan Pardeep
Nijhawan Pardeep
Nijhawan Pardeep
Institutional holders
Dividends & Stock splits
Comparable stocks
Frequently asked questions about Edesa Biotech stock
What does Edesa Biotech do?
Edesa Biotech, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in Canada.
The CEO is Pardeep Nijhawan, the company employs around 17 people.
The IPO was on 21/06/2010; the stock trades on NASDAQ under the ticker EDSA.
What do analysts say about Edesa Biotech stock?
2 analysts rate the stock, the consensus is Buy (as of 03/11/2025).
This is an external assessment, not a statement by Market Jury.
When does Edesa Biotech report next?
The next earnings date is 11/12/2026.
Around past earnings, price swings were roughly 20% stronger than usual.
Does Edesa Biotech pay a dividend?
No, Edesa Biotech currently does not pay a dividend.
Which stocks are comparable to Edesa Biotech?
Comparable stocks include AbCellera Biologics, Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines and Incyte.
How can I get Edesa Biotech stock analyzed?
Clicking "Analyze stock" lets five strategies assess Edesa Biotech against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.